OWP Pharmaceuticals announced that the U.S. Food and Drug Administration has approved SUBVENITE® Oral Suspension, the first and only lamotrigine oral suspension in the United States. This milestone addresses a significant gap in treatment options for patients who have difficulty with solid dosage forms or require precise dose adjustments.
Addressing Unmet Medical Needs
Lamotrigine is widely prescribed for neurological and psychiatric conditions, but until now only solid oral dosage forms have been available. SUBVENITE® Oral Suspension is specifically designed for patients who have difficulty swallowing tablets, those who require individualized dosing, or prefer liquid medication formulations.
"The FDA approval of SUBVENITE® Oral Suspension — the first and only lamotrigine oral suspension — represents a significant advancement in patient care," said Scott Boyer, Founder and President of OWP Pharmaceuticals. "We are proud to bring this much needed treatment option to patients and clinicians, with availability anticipated later in 2025."
Clinical Applications and Indications
SUBVENITE® is indicated for multiple therapeutic areas across different age groups. For epilepsy treatment, the suspension serves as adjunctive therapy in patients aged 2 years and older for partial-onset seizures, primary generalized tonic-clonic seizures, and generalized seizures of Lennox-Gastaut syndrome.
The formulation also supports monotherapy conversion in patients aged 16 years and older with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. Additionally, SUBVENITE® is approved for maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy.
Formulation Advantages
The liquid formulation offers several key benefits over traditional tablet forms. The precision dosing capability allows for dose titration and flexibility, particularly important for pediatric patients and those requiring individualized treatment regimens. The therapeutic reliability of SUBVENITE® has been developed to deliver the expected safety and efficacy profile as lamotrigine tablets.
Market Availability
SUBVENITE® Oral Suspension has received FDA approval and is expected to be available in the United States later in 2025 through leading distribution channels. Full prescribing information is available at www.owppharma.com.
Company Background
OWP Pharmaceuticals is a privately held, commercial-stage neuroscience specialty pharmaceutical company based in Chicago, dedicated to developing and commercializing novel oral liquid formulations. The company is committed to advancing therapies in neurology and psychiatry, with a mission to bring meaningful innovations to patients. Through its partnership with the ROW Foundation, OWP also supports global initiatives to improve epilepsy care and education in underserved communities worldwide.
